A Prospective Randomized Comparative Dosing Trial of Ranibizumab in Bevacizumab-Resistant Diabetic Macular Edema

To assess the efficacy of ranibizumab for persistent diabetic macular edema (DME) previously treated with bevacizumab and compare monthly vs treat-and-extend (TAE) dosing.12-month, open-label, prospective randomized comparative dosing study.27 participants with persistent foveal-involving DME recently treated with bevacizumab.All subjects were to receive three initial monthly 0.3 mg ranibizumab injections before randomization to monthly (n=15)...